Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs

Interview with Dr. Kevin Schulman on the recent approval of two PCSK9 inhibitors and what their prices could mean for insurance premiums. (09:12)Download Despite limitations in the data on the two new PCSK9 inhibitors, an FDA advisory committee has voted to approve alirocumab and evolocumab. But committee members emphatically stated that LDL cholesterol levels are not a reliable surrogate for cardiovascular benefit.